- Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
Watch Biogen's latest callBiogen (NASDAQ:BIIB) Q2 2026 Earnings Call · Replay · Jul 29Read the transcript of Biogen (NASDAQ:BIIB) Q2 2026 Earnings CallBiogen's next earnings callBiogen (NASDAQ:BIIB) Q3 2026 Earnings Call · Oct 28, 2026 at 8:30 AM EDTRegister
Story so far
- Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
- Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
- Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
Earlier from Biogen
- Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer
- Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
- Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
- Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
- Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
Later from Biogen
- Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
- New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
- Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
- Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
- Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors
Follow Biogen into a list and get an email when it puts out news.
Follow Biogen